Amgen considers Turkey as a regional biopharmaceutical hub

| By | Amgen, Investments, Pharmaceutical Industry
714

The increase experienced in the domestic industry with the incentives issued by the government in a support program, which included the pharmaceutical industry among primary strategic products, world giants turned their eyes to Turkey.

Amgen, a biopharmaceutical company headquartered in California, USA, invested $35 million in biotech medicine in Istanbul. Mr. Felix Thomas, Global Research and Development Director of Amgen, said Turkey’s expansion in pharmaceuticals is very important.

“If high value-added products are produced, Turkey will have a strategic importance for the region,” Thomas said.

Listed among the top 500 companies by Fortune magazine in 2016 with a turnover of $22.5 billion, Amgen purchased Mustafa Nevzat, Turkey’s largest pharmaceutical company, in 2012 for $700 million.

Amgen made the largest investment in all areas at once in Turkey. With that it brought biotechnological and biosimilar production technology to Turkey. The company made an additional investment of $35 million in biotechnology in Istanbul facilities last year, chose Turkey as a hub in the region.

Mr. Thomas also pointed that the global health sector is moving toward biotechnology. He stressed that biological drugs, which are difficult to produce in complex structures, should be produced in the highest quality, adding that quality is also of vital importance in biosimilar products.

Biotechnological drugs transform proteins obtained by genetically engineering the DNA of the live cells into drugs, are being used in the treatment of more than 800 million patients worldwide.

SOURCE: daily sabah
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.